If you are:
FDB Only When Necessary: INSUF HUMAN DATA; CNS STIMULANTS CROSS PLACENTAL BARRIER
Precaution: INSUFFICIENT DATA AVAILABLE, LIMITED DATA SUGGEST MINIMAL EXCRETION
An adult over 60:
management or monitoring precaution: Neuro/Psych-May exacerbate pre-existing insomnia. Cardiovascular-May exacerbate pre-existing or underlying cardiac abnormality, peripheral vasculopathy. Gastrointestinal-Anorexia may cause significant weight loss.
Giving methylphenidate ER tablet, extended release to a child under 12:
management or monitoring precaution: Risk of serious adverse event with underlying cardiac structural abnormality or other cardiac condition. Monitor appetite, growth, behavioral changes including suicidal ideation. Rare risk of priapism. Manufacturer does not recommend age < 6 years.
Severe Precaution: Risk of serious adverse event with underlying cardiac structural abnormality or other cardiac condition. Other risks; growth suppression, behavioral changes, suicidal ideation, new or breakthrough seizure. Not recommended age < 4 years (AAP). Safety and efficacy not established age < 6 years per manufacturer.